Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORTH CHICAGO, Ill., Feb. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial...

AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference

AbbVie (ABBV) signs an agreement to research and develop two new CAR-T cell therapies. The FDA approves label expansion of Botox for pediatric patients.

AbbVie (ABBV) Inks CAR T Deal, Gets Botox Label Expansion Nod

AbbVie Inc (NYSE: ABBV) and Caribou Biosciences have entered into a multi-year collaboration and license agreement to research and develop chimeric antigen receptor (CAR)-T cell therapeutics. AbbVie will utilize Caribou's Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie, and it will have exclusive rights to Caribou's genome editing and cell therapy technologies for the selected targets.

AbbVie, Caribou Biosciences Ink Licensing Agreement For (CAR)-T Cell Therapeutics

NORTH CHICAGO, Ill. and BERKELEY, Calif., Feb. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the...

AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products

AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy AbbVie (ABBV) Now

AbbVie stock flirted with a buy zone in early February after the company topped fourth-quarter views and issued upbeat 2021 guidance. The company also has the option to buy Cypris Medical.

AbbVie Posts A Massive Growth Quarter — Is It Time To Add AbbVie Stock?

AbbVie Inc.'s (ABBV) CEO Richard Gonzalez on Q4 2020 Results - Earnings Call Transcript

Amazon

Bristol-Myers

Spotify

Amazon, Spotify, Bristol-Myers Squibb and AbbVie were our top stock trades for Thursday. Let's look at the charts of these earnings movers.

4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV

Better-than-expected top and bottom lines plus positive guidance were exactly what Wall Street wanted.

Here's Why Investors Liked AbbVie's Q4 Results

AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.

AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright

AbbVie (ABBV) delivered earnings and revenue surprises of 2.46% and 0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates

AbbVie earnings and sales beat fourth-quarter estimates, with the pharmaceutical company guiding higher on 2021 EPS. AbbVie stock rose slightly.

AbbVie Stock: AbbVie Earnings Top Estimates, Guidance Strong

Shares of AbbVie (NYSE:ABBV) rose 1.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 32.13% over the past year to $2.92, which beat the estimate of $2.85.

AbbVie: Q4 Earnings Insights

Shares of AbbVie Inc. rallied 1.7% in premarket trading Wednesday, after the biopharmaceutical company reported fourth-quarter profit and revenue that beat expectations, and provided an upbeat full-year outlook. Net income dropped to $36 million, or 1 cent a share, from $2.80 billion, or $1.88 a share, in the year-ago period.

AbbVie stock rallies after profit and revenue beats, upbeat outlook

NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite...

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

On Wednesday, February 03, AbbVie (NYSE:ABBV) will release its latest earnings report. Here is Benzinga's outlook for the company.

Earnings Outlook for AbbVie

AstraZeneca

Gilead Sciences

Viatris

Merck

Pfizer

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipelines appeared first on InvestorPlace.

7 Pharmaceutical Stocks With Compelling Pipelines

AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?

Today we're seeing some of the most extreme speculation in history, including bankrupt companies soaring 700% in a single day. The difference between speculation and investment is the long-term risk profile. Sound investing over time = guaranteed success, while speculating for long enough = guaranteed losses.

5.1% Yielding AbbVie Is A Safe Anti-Bubble Blue-Chip In A Dangerous Bubble Filled Market

Amgen

Biogen

Alexion Pharma

Regeneron Pharmaceuticals

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week

AbbVie is quickly diversifying its business. It has a strong track record and attractive growth prospects.

AbbVie Is A Buy Even After The Recent Run Up

Brookfield Infrastructure Partners L.P.

Innovative Industrial Properties

You can count on the dividends flowing and growing with these stocks.

These Dividend Stocks Are Practically Money Machines

Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3.

Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?

Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.

Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?

Altria

Polaris

The stimulus euphoria rally continues, with the S&P just notching another record high and becoming 39% historically overvalued. But in every market there are blue-chip bargains available, even among the legendary dividend aristocrats.

News for AbbVie Stock (ABBV)